インドにおける肥満症ひまんしょう治療薬ちりょうやくの市場しじょう革命かくめいとその社会的しゃかいてき影響えいきょう

At Shivaji Park in Mumbai, Indias commercial city, you can see people taking care of their health by brisk walking, while nearby, around the food stalls, there are also people enjoying fried foods and sweets lined up along the street, checking their physical activity with pedometers as they eat.

As obesity treatments are about to emerge, these contrasting scenes vividly highlight the intersection of health-conscious trends and excessive eating habits.

Next month, as the patent for semaglutide, the main ingredient in Novo Nordisks obesity drug Ozempic, a major Danish pharmaceutical company, expires, the Indian pharmaceutical industry is competing to launch generic versions.

According to analysts, due to intense price competition, the price of obesity drugs in India could drop by as much as 90%.

Jefferies predicts that the semaglutide market in India will exceed $1 billion about 155 billion yen.

Namit Joshi, Chairman of the Pharmaceuticals Export Promotion Council of India Pharmexcil, said in an interview with CNN, We are ready.

Once the patent for this drug expires, it will undoubtedly flood the market.

Intensifying price competition in the obesity treatment drug market, strategic moves by Indian pharmaceutical companies, and market expansion through low-priced products are creating a new model in the global healthcare market.

Biocon, headquartered in southern Bangalore, is strengthening its injectable drug production with an investment of up to $100 million and is also aiming to export to Mexico and Brazil.

Dr. Reddy’s Laboratories, a competitor of this company, has announced plans to launch generic drugs in 87 countries, making the market competition increasingly fierce.

Due to the effects of price competition, the price of obesity treatments is expected to drop to $77 within the next year and eventually reach around $40.

This price reduction is expected not only to bring significant benefits to patients who need obesity treatment medication, but also to greatly boost demand that had previously been suppressed by high drug prices.

For obese patients, the emergence of this new option has the potential to significantly improve their quality of life.

Mr. Mahesh Chamadia, a 70-year-old resident of Mumbai, said that despite years of dieting and exercise with no results, using semaglutide brought his diabetes-related numbers back to normal and greatly improved his daily life.

However, the rapid expansion of the market is also accompanied by concerns about side effects and misuse.

In some clinics, obesity medications are being used as part of beauty programs before weddings, and experts are warning about the risks of misuse.

Semaglutide is only a part of the treatment, and it is emphasized that unless it is combined with overall lifestyle improvements such as exercise and diet, the expected effects cannot be maximized.